Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT-7695
- Development stage
- Preclinical
- Lead developer
- WARF Therapeutics
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
WT-7695 is a best-in-class radiopharmaceutical designed to target carbonic anhydrase IX (CA9), a protein highly expressed in certain cancers, notably clear cell renal cell carcinoma (ccRCC). The drug consists of a CA9-targeting ligand labeled with the therapeutic radioisotope lutetium-177 (Lu-177), specifically using SHINE Technologies' non-carrier added Lu-177 chloride product known as Ilumira. Preclinical studies have demonstrated that WT-7695 achieves high tumor uptake and retention, resulting in significant tumor regression and 100% survival in mouse models of kidney cancer. The agent delivers targeted radiation to tumors while minimizing exposure to healthy tissue. IND-enabling studies are planned for early 2025[1][2][3][6][7].
- Other names
- SK-CA9SK-CA-9SK-CA 9
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on WT-7695.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT-7695.